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Abstract
Summary: Large numbers of rare and unique titin missense variants have been discovered in both
healthy and disease cohorts, thus the correct classification of variants as pathogenic or non-
pathogenic has become imperative. Due to titin’s large size (363 coding exons), current web appli-
cations are unable to map titin variants to domain structures. Here, we present a web application,
TITINdb, which integrates titin structure, variant, sequence and isoform information, along with
pre-computed predictions of the impact of non-synonymous single nucleotide variants, to facilitate
the correct classification of titin variants.
Availability and implementation: TITINdb can be freely accessed at http://fraternalilab.kcl.ac.uk/
TITINdb
Contact: franca.fraternali@kcl.ac.uk
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
The giant protein titin, encoded by the gene TTN, is 35 991 amino
acids in length [inferred complete (IC) isoform], weighs over
4000 kDa and spans half a sarcomere. Since the advent of next gen-
eration sequencing (NGS) technology, a number of titin missense
variants, both recessive and dominant, have been associated with
disease (both skeletal and cardiac forms of myopathy) (Chauveau
et al., 2014a; Hastings et al., 2016; Helle et al., 2016; Savarese
et al., 2016), including those which can lead to sudden cardiac death
[e.g. hypertrophic cardiomyopathy (HCM)]. Unfortunately, due to
titin’s large size, even the majority of healthy individuals possess one
or more rare titin missense variants (Lopes et al., 2013). This results
in the paradox that rare titin variants are commonly found; there-
fore, pathogenicity cannot be inferred from frequency alone. To
complicate matters further, it has recently been shown that certain
titin variants can be pathogenic in particular constellations or act as
phenotype modifiers (Evil€a et al., 2014). One such scenario is the in-
heritance of a truncating variant along with a rare or unique mis-
sense variant in compound heterozygosity [as has been observed in
childhood core myopathy with heart disease, with rare recessive mu-
tations also found in the general population (Chauveau et al.,
2014b)]. In light of this information, we believe the assessment of
the impact of non-synonymous single nucleotide variants (nsSNVs)
at the molecular level to be essential, and propose that in silico
analyses can be used to prioritise variants for further experimental
investigation. We have created TITINdb to facilitate such
prioritization.
2 Implementation and features
TITINdb includes disease-associated nsSNVs reported in the litera-
ture as well as population nsSNVs from the gnomAD database (Lek
et al., 2016) and 1000 genomes project (Auton et al., 2015).
Additionally, in silico saturation mutagenesis has been performed to
allow users to access predictions for the impact of any possible sin-
gle amino acid variants (SAVs). As experimental structures were
only available for 23 of titin’s 302 globular domains (132 Fn3, 169
Ig, 1 Kinase), an automated pipeline based on the Modeller software
(Webb and Sali, 2016) was set up to model all 279 domains without
structure (see Supplementary Figure S3 for more details). As major
bioinformatics resources did not agree on titin domain numbers and
boundaries, we found it necessary to define these prior to modelling.
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As illustrated in Supplementary Figure S6, the TITINdb pipeline has
greatly increased the structural coverage of titin domains and the
quality of the coverage.
Sequence-based prediction of the impact of all nsSNVs was per-
formed using the Condel software (Gonzalez-Pe´rez and Lopez-
Bigas, 2011). The in silico assessment of the impact of nsSNVs using
structural information was performed using the DUET software
(Pires et al., 2014a) for all known nsSNVs which map to domain
structures, additionally the mCSM software (Pires et al., 2014b) was
used to predict the impact of all possible SAVs. Where experimental
structures of titin domains in complex with binary interaction part-
ners exist, mCSM was also used to predict the impact of SAVs on
protein–protein binding affinity. Other structural analysis provided
by the application includes computation of the quotient solvent ac-
cessible surface area [Q(SASA)] of all residues which map to struc-
ture [calculated using POPS (Cavallo et al., 2003)] and predictions
of which residues are involved in protein–protein interactions [cal-
culated using SPIDDER (Porollo et al., 2007)]. Of note, however, is
the absence of experimental, molecularly resolved protein–protein
interaction data for most of titin’s domains, precluding detailed im-
pact analysis on protein–protein interactions. Additionally, nsSNVs
are annotated with functional site information from UniProt (The
UniProt Consortium, 2017), including residue modifications.
Representative structures for each domain were used in the com-
putation of all structural analyses, apart from the calculation of
Q(SASA). This was calculated separately for each structure. A list of
structure representatives can be found in the Supplementary Tables
S1 and S2.
The application enables users to perform a number of visual-
izations, which include viewing population nsSNVs as distributions
on structures, colour-coded by minor allele frequencies.
Additionally, users are able to confidentially upload their own struc-
ture for nsSNV visualization (this may be useful if a group has an
unpublished crystal structure or believe their own model to be of
better quality).
All structures and in silico analyses can be freely accessed and
downloaded. Additionally, we provide quality assessment of the
models (in the form of zDOPE scores and per-residue DOPE plots)
(Shen and Sali, 2006) along with the alignments used for homology
modelling.
Video tutorials showing the use of TITINdb can be found at
http://fraternalilab.kcl.ac.uk/TITINdb/tutorials/
3 Applications
3.1 Investigating disease associated nsSNVs
A potential application of TITINdb that involves investigating SNVs
associated with specific diseases is shown in Figure 1 and further
explored in section S2.1 of the Supplementary Materials. The facility
to search by disease enables the detection of patterns or hotspots
characteristic of variants associated with particular diseases. Two
known nsSNV hotspots exist: one in domain Fn3-119 associated
with hereditary myopathy with early respiratory failure (HMERF)
(Pfeffer et al., 2015) and one in Ig-169 associated with tibial muscu-
lar dystrophy, limb-girdle muscular dystrophy 2J (TMD/LGMD2J)
(Chauveau et al., 2014a; Hackman et al., 2002; Savarese et al.,
2016).
TITINdb facilitates the visualization of nsSNVs associated with
these diseases on structure (see Fig. 1); for both conditions nsSNVs
can be observed to cluster in 3D space. In each case it can also be
clearly seen that the distribution of disease associated nsSNVs on
3D structure is distinct from the distribution of population nsSNVs
from the gnomAD database. Furthermore it becomes clear that all
disease-associated nsSNVs discussed here are fairly buried (as indi-
cated by a burgundy colour); therefore, it appears likely that they
may disrupt protein stability. From the pre-calculated in silico ana-
lysis, it can be seen that all these disease associated nsSNVs are pre-
dicted to be destabilizing by DUET (Pires et al., 2014a). TMD
associated nsSNVs are also predicted, by mCSM (Pires et al.,
2014b), to disrupt the interaction between titin and obscurin, albeit
by varying magnitudes; this has been validated experimentally
(Fukuzawa et al., 2008; Rudloff et al., 2015). Interestingly the
I35947N variant is predicted to have the least impact on the titin-
obscurin interaction affinity (mCSM score -0.17 kcal/mol) out of all
the TMD associated variants; this correlates with in vitro experi-
mental observations where negligible differences have been found
between this variant and wild-type titin (Fukuzawa et al., 2008;
Rudloff et al., 2015). Additionally, the majority of HMERF associ-
ated nsSNVs are predicted to be deleterious by Condel (Gonzalez-
Pe´rez and Lopez-Bigas, 2011), whereas only half the TMD
associated nsSNVs are predicted to be deleterious. This highlights
the need to take into consideration multiple sources of information,
as provided by TITINdb, when predicting the potential impact of
nsSNVs, and does not exclude experimental validation on a case-
by-case basis.
Despite being a hotspot for HMERF associated nsSNVs, no ex-
perimental PDB structures or models are currently publicly avail-
able for the domain Fn3-119. Therefore, TITINdb has made
possible the visualization of HMERF nsSNVs on structure and the
in silico prediction of their impact at the molecular level. Multiple
PDB structures exist for the domain Ig-169 (commonly referred to
as M-10), to which TMD associated nsSNVs localize. Here, users
can select which structure they wish to use to perform nsSNV
visualization.
3.2 Investigating NGS nsSNV data
An application of TITINdb we believe to be particularly useful is the
analysis of variants from NGS data. Specifically, the tool can be
used in the prioritization of rare variants observed in disease cohorts
for further experimental investigation. An example of such a variant
is the P13979S titin N2B (isoform) nsSNV, which is published in the
Supplementary Information associated with the article from Lopes
et al. (2013), and further described in Section S2.2 of the
Supplementary Materials. The nsSNV is found in 3/143 patients
with HCM, leading to a cohort minor allele frequency (MAF) of be-
tween 0.01 and 0.02 (details on zygosity are not available).
A notable feature of TITINdb is the ability to search by different
isoform positions. Tools such as ANNOVAR (Wang et al., 2010)
enable researchers to map variants from genomic to protein coordin-
ates, however, depending on the protocol followed, variants may be
mapped to different isoforms. For our nsSNV of interest, the N2B
isoform coordinate is reported, thus the ‘search by position’ facility
allows it to be mapped to both other major isoforms and the pos-
ition within the affected domain. Additionally, it can be seen that
the nsSNV localizes to residue position 5 of domain Fn3-55 and is
present in all isoforms apart from the novex-3 isoform; therefore it
is expressed in both cardiac and skeletal muscle.
TITINdb allows easy access to information concerning the
nsSNV’s potential impact. Structurally, it can be seen that the af-
fected residue has a Q(SASA) of 0.1 (this information is provided in
the table on the nsSNV page), indicating that it is buried and that
the nsSNV could potentially cause disease through destabilization of
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the underlying domain. It can also be seen, from predictions by the
software SPPIDER (Porollo et al., 2007), that the affected residue is
not predicted to be involved in protein-protein interactions and thus
is unlikely to cause disease through the disruption of these.
On comparison to known nsSNVs it can be seen that the nsSNV
is present in both the 1000 genomes data and the gnomAD database
with MAFs of 3.7036E-03 and 9.98403E-04. This indicates the vari-
ant is rare but present in a small proportion of nominally healthy in-
dividuals. From the MAF values it can be deduced that the variant is
enriched in the HCM cohort (which we know has a MAF between
0.01 and 0.02). This suggests that the variant is either neutral,
disease-causing with incomplete penetrance, recessive, or that a
small number of nominally healthy individuals have undiagnosed
HCM.
Structure (DUET)- and sequence (Condel)-based predictions of
the impact of the nsSNV can be observed. The DUET score of
2.703 kcal/mol suggests the variant is highly destabilizing and sup-
ports the hypothesis derived earlier from the Q(SASA) that the vari-
ant could potentially lead to disease by disrupting the domain
structure. Furthermore, it can be seen that the variant is also pre-
dicted to be deleterious by Condel.
As no experimental structures exist for the domain Fn3-55, 3D
visualization and access to pre-computed structural analyses are
made possible by the homology model provided as part of TITINdb.
One salient feature is that, if nsSNVs are pinned on structure from
the sequence, any related/identical nsSNVs rise to the top of the
nsSNV table and become highlighted in either yellow (surface) or
red (buried) according to their Q(SASA) (see Supplementary Figure
S2); the pinned nsSNVs also follow this colour scheme.
The results indicate that, although the analysed nsSNV is highly
likely to affect the domain structure, it is unclear whether this will
contribute to the disease phenotype (primarily as the mutant titin
may not be expressed in vivo in heterozygous cases).
Further information concerning applications of TITINdb can
be found in the Supplementary Materials. In particular, it is hoped
that the tool will enable clinicians to perform the information-
based assessment of variants from patient data, and assist biolo-
gists in the prioritization of domain structures for biophysical
characterization.
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